Clinical trials: Intravenous Therapy
Gram-Positive Bacterial Infections
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
- Trial name
- ASSURE (NCT00062647)
- Testing
- Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Cumberland Pharmaceuticals
Neoplasms
BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
This open-label phase I dose escalation trial, 1230.15, is the first trial with Volasertib in Japanese advanced cancer patients.
- Trial name
- NCT01348347
- Testing
- Volasertib, low dose, d1q3w, Volasertib, middle dose, d1q3w, Volasertib, high dose, d1q3w
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Cerebral Infarction
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction
The objective of the study is to evaluate the safety and the potential therapeutic effects per dose of Cordstem-ST Intravenous Transplantation in Cerebral Infarction subjects
- Trial name
- NCT02378974
- Testing
- Cordstem-ST
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- CHABiotech CO., Ltd
Anemia, Chronic Kidney Disease
Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease
To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00109291
- Testing
- peginesatide
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Affymax
Acute Decompensated Heart Failure
Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure
The purpose of this study is to evaluate the efficacy and safety of a continuous intravenous (IV) ularitide infusion on the clinical status and outcome of patients with acute decompensated heart failure (ADHF).
- Trial name
- TRUE-AHF (NCT01661634)
- Testing
- Ularitide
- Where
- 163 sites in United States, Argentina and 20 more
- Volunteers
- 2,157 people
- Sponsor
- Cardiorentis
Secondary Hyperparathyroidism, Chronic Kidney Disease
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
The purpose of this study is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum parathyroid hormone (PTH) levels by > 30% from baseline among patients with…
- Trial name
- NCT01896232
- Testing
- Etelcalcetide, Cinacalcet
- Where
- 182 sites in United States, Austria and 20 more
- Volunteers
- 683 people
- Sponsor
- Amgen
Iron Deficiency Anaemia
IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose
The purpose of the trial is to evaluate and compare the effect of iron isomaltoside 1000 to iron sucrose in its ability to increase haemoglobin (Hb) in subjects with IDA when oral iron preparations are ineffective or cannot be…
- Trial name
- Provide (NCT02130063)
- Testing
- iron isomaltoside 1000 (Monofer®), iron sucrose (Venofer®)
- Where
- United States
- Volunteers
- 511 people
- Sponsor
- Pharmacosmos A/S
Multiple Sclerosis, Relapsing-Remitting
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
- Trial name
- PRIVIG (NCT00220779)
- Testing
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 128 people
- Sponsor
- Grifols Therapeutics LLC
Advanced Malignant Solid Tumor
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to…
- Trial name
- NCT07682870
- Testing
- Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Virogin Biotech Ltd.
Crohn's Disease
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's…
- Trial name
- NCT06045754
- Testing
- Vedolizumab, Adalimumab, Ustekinumab
- Where
- 48 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Takeda
Skin Structures and Soft Tissue Infections
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
- Trial name
- REVIVE-1 (NCT02600611)
- Testing
- iclaprim, vancomycin
- Where
- 56 sites in United States, Bulgaria and 8 more
- Volunteers
- 600 people
- Sponsor
- Motif Bio
Restless Legs Syndrome (RLS)
Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)
The purpose of this study was to evaluate the safety of 2 dosage regimens of Intravenous (IV) iron Ferric Carboxymaltose (FCM) in comparison to placebo in patients with Restless Legs Syndrome (RLS)
- Trial name
- NCT01382901
- Testing
- Ferric Carboxymaltose (FCM)
- Volunteers
- 45 people
- Sponsor
- American Regent, Inc.
HER2+ Breast Cancer
Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer
This study evaluated the clinical benefits of intravenous administration of pyrotinib combined with trastuzumab subcutaneous preparation by comparing the efficacy and quality of life of intravenous administration in the treatment…
- Trial name
- NCT06537674
- Testing
- Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection
- Volunteers
- 100 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Crohn's Disease
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called…
- Trial name
- VICTRIVA (NCT06227910)
- Testing
- Vedolizumab, Upadacitinib
- Where
- 138 sites in United States, Austria and 24 more
- Volunteers
- 396 people
- Sponsor
- Takeda
Cytomegalovirus Infections, Cytomegalovirus Retinitis
Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient
To make intravenous (IV) ganciclovir available to immunocompromised patients with life-threatening or sight-threatening Cytomegalovirus (CMV) infection, where the symptoms of the disease are too severe to allow admission to a…
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Retinitis, HIV Infections
- Trial name
- NCT00002025
- Testing
- Ganciclovir
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Intracerebral Hemorrhage
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.
- Trial name
- NCT00075959
- Testing
- NXY-059
- Where
- 64 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Part A: To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of Xentuzumab (BI 836845) in combination with afatinib in patients with non-small cell lung cancer with progression following prior…
- Trial name
- NCT02191891
- Testing
- Xentuzumab, Afatinib
- Where
- 10 sites in Japan, Singapore and 2 more
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Cytomegalovirus Retinitis, HIV Infections
Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection
The purpose of this study is to make valganciclovir available, before it is approved for marketing, to HIV-infected patients who have cytomegalovirus (CMV) retinitis (eye infection) and cannot take drugs by injection.
- Trial name
- NCT00017784
- Testing
- Valganciclovir
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Invasive Candidiasis
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
To evaluate the efficacy and safety of anidulafungin in the treatment of systemic fungal infections in intensive care and critical care unit patients.
- Trial name
- ICE (NCT00689338)
- Testing
- Anidulafungin, Fluconazole, Voriconazole
- Where
- 61 sites in Austria, Belgium and 17 more
- Volunteers
- 216 people
- Sponsor
- Pfizer
Chronic Renal Failure With Hemodialysis
Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
A phase 2, randomized, open label, active comparator parallel controlled study to explore the dosage regiment of rESP, and evaluate its efficacy, safety and pharmacokinetic characteristics in the treatment of anemia in chronic…
- Trial name
- NCT03950687
- Testing
- Recombinant Human Erythropoiesis Injection (CHO cell), Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.